

Dear Lakehouse Investor,

March was another busy month for Lakehouse. Our team met with 7 companies, including an IPO hopeful, and was unusually active in both buying and selling during the month as we were armed with new information fresh off the back of the half-year results.

We topped up 3 existing positions where our investment thesis has strengthened, initiated a new position in a company we've been following for some time, completely sold out of another position where the investment thesis hasn't played out as expected, trimmed our stake in a company where our enthusiasm waned following the half-year update, and took profits on a position that has done exceptionally well to the point of creating position sizing issues.

The confluence of portfolio changes saw the Fund's cash position tick up slightly from 15.4% to 15.5% over the course of the month. That's a touch higher than our typical range of 5% to 15%, however, we expect to get back within a typical range soon as we're in the process of building a new position and actively evaluating new opportunities.

Turning to performance, the Fund returned 5.4% net of fees and expenses in March compared to a -0.1% return for the benchmark. For the fiscal year, the Fund has returned a net 12.7% compared to -1.8% for the benchmark. Since inception in mid-November 2016, the Fund has returned a net 66.9% compared to 28.5% for the benchmark.

We're pleased with the Fund's progress towards its ultimate objective of long-term outperformance, however, our team does not judge itself on short-term performance and neither should investors who embrace our long-term, high-conviction strategy.

The Fund's most significant contributor to performance during March was **LiveTiles** (+43.4%), which is a small, fast-growing enterprise software business that we plan to discuss next month. The biggest detractor was **Bapcor** (-8.6%), which we've discussed in these letters previously, as it drifted lower on no new information.

The Fund's five largest holdings as of the end of March accounted for 35.1% of the portfolio and are named in order of the Fund's allocation: **Afterpay Touch, Altium, Pro Medicus, Audinate** and

Companies Held:	21
Cash Allocation:	15.5%
Top 5 Portfolio Holdings:	35.1%
Net Asset Value per Unit:	\$1.5830
Fund Net Asset Value:	\$190.6 million
Benchmark:	S&P/ASX Small Ordinaries Accumulation Index

Nanosonics. While the first three positions are well known to Lakehouse investors as long-time holdings, last month was the first time we disclosed the Fund's holdings in Audinate and Nanosonics, and we'll discuss each in more detail shortly.

Zooming out, the Fund's largest sector allocations as of the end of the month were to information technology (66.7% of total capital), health care (13.1%), and consumer discretionary (3.4%), which is quite different to the benchmark's largest allocations: materials (19.0%), consumer discretionary (15.3%), and information technology (12.7%).

We continue to embrace a differentiated approach with an emphasis on companies and industries known for capital-light, recurring-revenue-centric business models. To that end, and considering the soft state of the Australian and Chinese economies, we are even more comfortable than usual being significantly underweight the likes of materials, consumer discretionary, and real estate.

Company News

As noted in last month's letter, Audinate and Nanosonics recently grew their way into top 5 positions, and have remained there at the end of March.

Audinate provides digital networking hardware and software to the professional audio-visual (AV) market and have established their 'Dante' platform as the global industry standard. In simple terms, traditional analogue AV requires a snakepit of physical cords and leads, whereas digital AV systems like Dante run over existing computer networks with much less fuss. Digital AV is simply a much better mouse trap for large, complex, or higher-end installations and Dante, with its ultra-low latency that makes for superior sound quality in large environments, has emerged as the leading digital platform.

Dante is far and away the leading digital protocol -- Dante is used in over 5x the number of products to the nearest competitor -- and the gap is widening as network effects continue to unfold. Dante's share of networked audio products in the market has increased from 58% to 71% over the past year and, based on our analysis of the numbers provided by the company to the ASX, roughly 99% of new networked audio products are running with the Dante protocol. As Phil Ochs sang, "I declare the war is over."

Original equipment manufacturers (OEMs) are rallying around Dante in a self-reinforcing fashion because the establishment of a clear platform winner removes the risks for OEMs of backing the wrong horse. Also, the large and growing number of Dante-powered products improves the value proposition and interoperability of new products. Given the establishment of a clear market leader we would expect to see the market expand as a result, and sure enough the total number of unique networked audio products on the market increased by almost 47% last year.

Over 1,800 Dante-enabled products are currently being shipped from around 230 manufacturers, with another 200-plus manufacturers signed-up and developing even more products. This pent up supply of new Dante-enabled product is like a coiled-spring and lays the foundation for continuing long-term growth given the typical 7 to 8 year audio hardware lifecycle, and the fact that the structural shift from analogue to digital is only 8% through.

Until recently Audinate focused on producing chips, cards, modules and software for the digital audio market only, and was delivering strong revenue growth from that segment -- in excess of 50%. However, in January 2019 Audinate released to market their digital video offering on the Dante network, roughly doubling the company's addressable market and paving the way to further boost revenue from FY20. Alongside this is a growing mix of Dante-software control systems, and Dante-trained technicians to install and service it all. In fact, Audinate trained 18,000 people in the last 6 months of 2018, which is equivalent to the cumulative number trained since the company started over 10 years ago.

Owning the dominant AV platform, in the early stages of a global structural shift, of a large and growing market exemplifies the type of long-term opportunities we seek. We think Audinate has a bright future and are happy to have a meaningful slice of the Fund's capital behind the company.

Nanosonics is the other large position that the Fund is discussing for the first time. There is a large and growing body of research driving a global trend toward stricter ultrasound probe cleaning, to reduce the avoidable spread of disease among ultrasound patients. For example, a recent clinical study in Japan found that over 90% of ultrasound probes were contaminated following cleaning at a university hospital and an ultrasound clinic. Nanosonics are at the forefront of this trend and have set a new standard for infection prevention in ultrasound probes through their patented Trophon devices.

The business operates a razor-and-blade-esque model: hardware devices are purchased or leased by ultrasound clinics, and the customer then repurchases consumable disinfectant cartridges at a much higher frequency. Consequently the business collects high levels of recurring revenue. The consumables are sold at very high gross margins, in the order of 90%, while the capital equipment is sold on lower -- but still very respectable -- gross margins and are replaced on average after a 5- to 7-year lifecycle. The company also offers a full 'as a service' model -- commonplace in the software space, but less so in healthcare -- which also has very attractive economics for the company.

Nanosonics has grown its topline at an average of 29.6% per year since 2014, while the global installed base has grown at a faster 42.2% per year, to almost 20,000 units today. The rapid growth in the installed base points to a strong base of recurring revenue from consumable sales, but the market itself could still grow multiples larger from its current 16% penetration.

Almost 90% of the installed base of units are in North America due to a long standing distribution agreement with GE. However, this mix is expected to change significantly in the coming years as European guidelines in large markets like France, Germany and United Kingdom tilt in Nanosonics favour, and distribution agreements in new markets continue to be signed. In the last half alone, Nanosonics expanded European distribution to include: Denmark, Finland, Portugal, Spain and Switzerland. Other prospective markets are at varying stages, ranging from; market assessment studies in China, to clinical studies in Japan, and regulatory approval in South Korea. Overall market penetration in Europe and the Middle East remains very low at around 2%, while Asia Pacific is roughly double but still very low, and the more mature North American is around 43% penetrated.

Nanosonics is very well positioned to drive their global expansion, with solid cash flow, a net-cash balance in excess of \$71 million, and continuing R&D investment toward future growth. The company has been busily working on a new high-level-disinfectant product for the past couple of years, and while management remains tight-lipped on the details, the new product is expected to be in market by late FY20 -- subject to regulatory approvals.

We are enthused by Nanosonics large global market opportunity, recurring revenue business model, fortress balance sheet, diverse customer footprint, and multiple futures it is building through ongoing R&D.

Looking Ahead

April is a lively month for us as some of the Fund's earlier-stage holdings will provide quarterly cash flow reports and business updates to the ASX. We look forward to getting the latest numbers and catching up with the leaders of some of those companies. We also have a number of company meetings planned for the month ahead as our search for compelling investment opportunities to put our investors capital behind continues.

As always, thanks to all our investors for your time and trust.

Best Regards,



Joe Magyer, CFA

Portfolio Manager, Lakehouse Small Companies Fund
Chief Investment Officer, Lakehouse Capital

Sole use and confidentiality: This report has been prepared by Lakehouse Capital Pty Limited (ABN 30 614 957 603, authorised representative of AFSL 400691) and by its officers, employees and agents (collectively "Lakehouse") for the sole use of its clients as a record of the performance of their investment. The contents of this report are confidential, and the client may only disclose such contents to its officers, employees or advisers on a need to know basis, or with the prior written consent of Lakehouse.

Disclaimer: The responsible entity for the Lakehouse Small Companies Fund (ARSN 615 265 864) is One Managed Investment Funds Limited (ACN 117 400 987) (AFSL 297042) ("OMIFL"). The information contained in this document was not prepared by OMIFL but prepared by other parties. All of the commentary, statements of opinion and recommendations contain only general advice and have not taken into account your personal circumstances. This report contains general financial product advice only. Any investment in Lakehouse or OMIFL products need to be made in accordance with and after reading the Product Disclosure Statement (PDS) and Additional Product Disclosure Statement (APDS) dated 15 March 2019, and investors should consider the PDS before deciding whether to invest in the Fund or continue to hold units in the Fund. The opinions, advice, recommendations and other information contained in this report, whether express or implied, are published or made by Lakehouse in good faith in relation to the facts known at the time of preparation. Information is current as at the date of the letter, unless otherwise noted. Past performance is not indicative of future performance. The PDS and APDS can be obtained by visiting www.oneinvestment.com.au/lakehouse.

Limitation of liability: Whilst all care has been taken in preparation of this report, to the maximum extent permitted by law, neither Lakehouse or OMIFL will be liable in any way for any loss or damage suffered by you through use or reliance on this information. Lakehouse and OMIFL's liability for negligence, breach of contract or contravention of any law, which cannot be lawfully excluded, is limited, at Lakehouse's option and to the maximum extent permitted by law, to resupplying this information or any part of it to you, or to paying for the resupply of this information or any part of it to you.

Disclosure: Lakehouse, its directors, employees and affiliates, may, and likely do, hold units in the Lakehouse Small Companies Fund and securities in entities that are the subject of this report. Copyright: Lakehouse owns the copyright to this publication. Its contents may be used for your own personal use, but you must not (without Lakehouse's consent) alter, reproduce or distribute any part of this publication, transmit it to any other person or incorporate the information into any other document.